



## Press release |

### **IBA MOLECULAR ADDRESSES NUCLEAR MEDICINE INDUSTRY'S MOLYBDENUM SHORTAGE WITH SOLUTIONS**

*Company focused on providing imaging specialists with alternative products unaffected by raw materials shortage for continued patient care*

**Gif-sur-Yvette, France, May 25<sup>th</sup>, 2010** – [IBA Molecular](#), member of [IBA group](#) and global developer of next generation radiopharmaceuticals, announced today that it has put in place a set of specific actions to mitigate the impact of the critical weeks of molybdenum (Mo99) shortage expected in the coming months.

The nuclear medicine industry's expected supply issues of the raw material Mo99 will require imaging specialists to find alternative diagnostic solutions to using the diagnostic tracer Technetium-99m (Tc99m) in patient scanning, so that they can continue to perform critical patient examinations during this time. IBA Molecular's sodium fluoride (NaF), used for bone scintigraphy, will be made available across Europe through the company's PET manufacturing network. Nuclear medicine professionals will also be able to rely on thallium chloride (thallium), a long-standing product in IBA's portfolio, to conduct myocardial scintigraphy without relying on Tc99m.

To allow nuclear medicine specialists to seamlessly replace Tc99m tracers with new, unfamiliar products, IBA Molecular is also making educational support available, to provide hands-on training on these new procedures to specialists who require assistance.

Additionally, IBA announced that, through its relationship with IRE (Institut des Radio-Elements), it has obtained additional quantities of Mo99 from the Nuclear Research Institute of REZ, located in the Czech Republic, which will allow it to maintain a greater Tc99m supply throughout the troubled weeks ahead.

Mo99 is a raw material that is central in the manufacturing of Tc99m generators used in nearly 60% of all patient scanning tests conducted by specialists. The nuclear medicine industry's manufacturing and supply issues are the result of aging reactors around the globe which experience repeated technical issues. Any halt in the production of Mo99 decreases the supply of products that are used by specialists in patient scans, resulting in fewer scans and a critical lack of diagnosis and treatment of potentially fatal diseases.

"Our unique manufacturing infrastructure and largest product portfolio enable us to address the molybdenum crisis head-on, to ensure that specialists can continue to operate, regardless of industry challenges," said François Labarre, vice president, Europe of IBA Molecular. "The critical weeks



## Press release |

ahead stress again the fragility of our discipline and the need for the entire community to invest in a more secure supply chain.”

###

### **About IBA Molecular and IBA group**

IBA Molecular is global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. With radiopharmaceutical discovery-to-delivery development capabilities that address indications in oncology, cardiology and neurology, in PET, SPECT and therapy, IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic tracers aimed at contributing to the development of the global trend towards personalized medicine and making molecular imaging a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs. IBA Molecular was awarded Frost & Sullivan’s European Radiopharmaceuticals Technology Leadership of the Year prize in 2010. Headquartered in Gif-sur-Yvette, France, IBA Molecular is a member of the Belgium-based IBA group. IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Please visit [www.iba-molecular.com](http://www.iba-molecular.com) and [www.iba-worldwide.com](http://www.iba-worldwide.com) for more information about IBA Molecular and IBA group.

#### Media contact:

Christina Aplington  
Ballou PR for IBA Molecular  
+33 – 01 42 22 93 65  
[christina@balloupr.com](mailto:christina@balloupr.com)